Ismail Kola - Athersys Independent Director
| ATHXDelisted Stock | USD 0.01 0 18.75% |
Director
Dr. Ismail Kola, Ph.D., is Independent Director of Athersys, Inc. Dr. Kola has served as a Director since October 2010. Dr. Kola was Executive Vice President of UCB S.A. in Belgium, a biopharmaceutical company dedicated to the development of innovative medicines focused on the fields of central nervous system and immunology disorders, and President and Chief Scientific Officer of UCB New Medicines, UCBs discovery research through to proofofconcept in man organization, from November 2009 until his retirement in December 2017. Dr. Kola was formerly Senior Vice President, Discovery Research and Early Clinical Research Experimental Medicine at ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationration, a pharmaceutical company, and Chief Scientific Officer at ScheringPlough Corporationrationration, from March 2007 until his appointment at UCB. Prior to ScheringPlough, Dr. Kola held senior positions from January 2003 to March 2007 at Merck, a pharmaceutical company, where he was Senior Vice President and Site Head, Basic Research. From 2000 to 2003, Dr. Kola was Vice President, Research, and Global Head, Genomics Science and Biotechnology, at Pharmacia Corporationrationration, a pharmaceutical company. Prior to his position with Pharmacia, Dr. Kola spent 15 years as Professor of Human Molecular Genetics and was Director of the Centre for Functional Genomics and Human Disease at Monash Medical School in Australia. Dr. Kola received his Ph.D. in Medicine from the University of Cape Town, South Africa, his B.Sc. from the University of South Africa, and his B.Pharm. from Rhodes University, South Africa. Dr. Kola served on the board of directors of Biotie Therapies, Inc. from February 2011 until May 2016 when it was sold to Acorda Therapeutics, where he also served on the compensation committee. Dr. Kola served on the boards of directors of Astex Therapeutics . since 2010.
| Age | 61 |
| Tenure | 14 years |
| Professional Marks | Ph.D |
| Phone | 216 431-9900 |
| Web | www.athersys.com |
Athersys Management Efficiency
The company has return on total asset (ROA) of (1.0409) % which means that it has lost $1.0409 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.7602) %, meaning that it created substantial loss on money invested by shareholders. Athersys' management efficiency ratios could be used to measure how well Athersys manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 9.43 M in liabilities. Athersys has a current ratio of 0.53, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Athersys until it has trouble settling it off, either with new capital or with free cash flow. So, Athersys' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Athersys sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Athersys to invest in growth at high rates of return. When we think about Athersys' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Jodie Morrison | Akebia Ther | 42 | |
| Michael Rogers | Akebia Ther | 58 | |
| Duane Nash | Akebia Ther | 46 | |
| David Barrett | Fortress Biotech | 39 | |
| Michael Dougherty | Trevena | 60 | |
| Mark Enyedy | Akebia Ther | 54 | |
| Michael Clayman | Akebia Ther | 64 | |
| Scott Canute | Akebia Ther | 56 | |
| Mark Ternouth | Virax Biolabs Group | 56 | |
| CPA CPA | Sonnet Biotherapeutics Holdings | 75 | |
| Julie McHugh | Trevena | 53 | |
| Michael Heffernan | Akebia Ther | 53 | |
| Jake Nunn | Trevena | 47 | |
| Chunyuan CPA | YS Biopharma Co | 46 | |
| Cynthia Smith | Akebia Ther | 49 | |
| Jay Lobell | Fortress Biotech | 51 | |
| Anne Phillips | Trevena | 64 | |
| Barbara Yanni | Trevena | 62 | |
| Maxine Gowen | Akebia Ther | 60 | |
| Yuan Liu | YS Biopharma Co | 37 | |
| Jimmie Harvey | Fortress Biotech | 62 | |
Management Performance
| Return On Equity | -12.76 | |||
| Return On Asset | -1.04 |
Athersys Leadership Team
Elected by the shareholders, the Athersys' board of directors comprises two types of representatives: Athersys inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Athersys. The board's role is to monitor Athersys' management team and ensure that shareholders' interests are well served. Athersys' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Athersys' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kasey Rosado, Interim Officer | ||
| Ellen Gurley, Mang Relations | ||
| Lorin Randall, Independent Director | ||
| Kenneth Traub, Independent Director | ||
| Robert Deans, Executive VP of Regenerative Medicine | ||
| Lee Babiss, Independent Director | ||
| William Lehmann, President COO | ||
| MBA MD, Ex Affairs | ||
| Robert Mays, Head VP | ||
| Daniel MBA, Sec, CEO | ||
| Ismail Kola, Independent Director | ||
| MS MBA, Chief Officer | ||
| Alison MBA, VP HR | ||
| Gil Bokkelen, Co-Founder, Chairman and CEO | ||
| John Harrington, Co-Founder, Chief Scientific Officer, Executive VP and Director | ||
| Jack Wyszomierski, Independent Director | ||
| PMP BS, Ex Manufacturing | ||
| Laura Campbell, Vice President - Finance | ||
| Jordan Davis, Independent Director | ||
| Rakesh MS, Head VP |
Athersys Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Athersys a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -12.76 | |||
| Return On Asset | -1.04 | |||
| Operating Margin | (260.55) % | |||
| Current Valuation | 24.52 M | |||
| Shares Outstanding | 26.71 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Shares Owned By Institutions | 11.30 % | |||
| Number Of Shares Shorted | 993.2 K | |||
| Price To Earning | 0.39 X | |||
| Price To Book | 219.57 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Athersys in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Athersys' short interest history, or implied volatility extrapolated from Athersys options trading.
Pair Trading with Athersys
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Athersys position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Athersys will appreciate offsetting losses from the drop in the long position's value.Moving against Athersys Pink Sheet
| 0.68 | CVX | Chevron Corp Earnings Call This Week | PairCorr |
| 0.62 | GE | GE Aerospace Financial Report 23rd of July 2024 | PairCorr |
| 0.61 | XOM | Exxon Mobil Corp Earnings Call This Week | PairCorr |
| 0.61 | MRK | Merck Company Earnings Call Tomorrow | PairCorr |
| 0.53 | CAT | Caterpillar Earnings Call Tomorrow | PairCorr |
The ability to find closely correlated positions to Athersys could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Athersys when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Athersys - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Athersys to buy it.
The correlation of Athersys is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Athersys moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Athersys moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Athersys can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. Note that the Athersys information on this page should be used as a complementary analysis to other Athersys' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Athersys Pink Sheet
If you are still planning to invest in Athersys check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Athersys' history and understand the potential risks before investing.
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |